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A B S T R A C T
Neuroendocrine tumors are the most common nonsquamous types of laryngeal neoplasms. They are classified as typi-
cal carcinoids, atypical carcinoids, small-cell neuroendocrine carcinomas, and paragangliomas. The aim of the paper is
to present four patients with small-cell neuroendocrine tumor arising in larynx. There were one woman and three men
whose ages were 47–77 years; all of them had metastases when first seen. The clinical presentation and management of
such type of tumor are discussed. Small-cell neuroendocrine carcinomas are very aggressive neoplasms. Patients could
benefit from surgery, but radiotherapy and chemotherapy remain the treatment of choice. Examination of a large series is
required to define the most useful diagnostic methods and the most successful treatment modalities.
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Introduction
Laryngeal cancer is the most common head-and-neck
cancer and accounts 2.4% of new cancer diagnoses annu-
ally in men1. Squamous cell carcinoma accounts for more
than 90% of laryngeal cancers and it is the most common
histologic finding. Neuroendocrine tumors are the most
common nonsquamous types of neoplasms arising in lar-
ynx and represent <1% of all primary laryngeal tumors2.
Gastrointestinal tract is the commonest site for the
occurrence of neuroendocrine tumors (about 70% of ca-
ses) followed by the respiratory tract (about 25%). The
first laryngeal neuroendocrine tumor (atypical carcinoid
tumor) was reported in 1969 by Goldman et al.3. These
tumors have a predilection for the supraglottis4. Most pa-
tients are males, 50 to 70 years of age at presentation and
more than 70% of them have a history of smoking.
Neuroendocrine tumors of the larynx represent a het-
erogeneous group of neoplasms. The World Health Orga-
nization classified these tumors into 4 subtypes: typical
carcinoid (well differentiated neuroendocrine carcinoma,
grade I), atypical carcinoid tumor (moderately differenti-
ated neuroendocrine carcinoma, grade II; large cell neu-
roendocrine carcinoma), small cell neuroendocrine carci-
noma (poorly differentiated neuroendocrine carcinoma,
grade III), and paragangliomas5. The most frequent type
is the atypical carcinoid, while the typical carcinoid is a
very rare tumor.
Small-cell neuroendocrine tumors of larynx are very
rare. Histologically, they are divided into 3 types: oat cell,
intermediate cell, and combined variants. Light micros-
copy is usually diagnostic but in some instances must be
supported by immunohistochemistry which reveals po-
sitivity for either epithelial or neuroendocrine markers.
This tumor is highly aggressive and should be considered
disseminated at initial diagnosis. The treatment is by
chemotherapy and radiotherapy. Surgery for this tumor
should be reserved for cases of local relapse with no evi-
dence of metastasis. The prognosis of these patients is
the worst, with 5-year survival rates of 5%6. The survival
rates are similar to those for small cell lung cancer and
do not correlate with the tumor size.
In this paper we present the clinical and histopatho-
logical features of 4 cases of small-cell neuroendocrine
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tumors of the larynx. Two patients were diagnosed and
treated at Clinical center of Serbia, Belgrade, a 2 of them
at the Clinical center of Montenegro, Podgorica. We also
review previously published papers on the diagnosis and
treatment of these rare neoplasms.
Case Report 1
A 54-year-old male, tobacco smoker, presented with
bilateral cervical lymphadenopathy, hoarse voice and dif-
ficulty breathing progressively getting worse for the last
2 years. An indirect laryngoscopy was performed which
revealed a large supraglottic mass extending to the ton-
gue base. A tracheostomy was placed and patient under-
went laryngoscopy and biopsy. The histopathological eva-
luation revealed a poorly differentiated neuroendocrine
carcinoma. Immunohistochemistry was diffusely positive
for synaptophysin and chromogranin-A. Immunohisto-
chemistry for cytokeratins (CK) 5/6 and p63 was nega-
tive. Immunohistochemistry for Ki-67 showed 50% of the
cells to be positive. No distant metastases were identified
by radiology. Pharyngolaryngectomy with bilateral neck
dissections was performed. Metastatic carcinoma was
present in 14 of 24 lymph nodes. The patient was disease
free after 15 months of follow up.
Case Report 2
A 67-year-old man, a known smoker for more than 45
years, presented with dysphonia for over 4 months. La-
ryngoscopy showed an exophytic mass at the epiglottic
base extending to the both true vocal cord. On examina-
tion he had a 2.0 cm left neck mass. Radiologic studies
showed no evidence of metastatic disease. A biopsy of la-
ryngeal mass was interpreted as poorly differentiated
neuroendocrine carcinoma, grade III. Immunohistoche-
mistry revealed expression of synaptophysin, neuron-
-specific enolase (NSE), chromogranin-A and CD56. Im-
munohistochemistry for CK 5/6, CK19, p63 and TTF1
(thyroid transcription factor-1) was negative. Subtotal
laryngectomy and neck dissections were performed. On
last follow-up 2 months after his operation, he had no ev-
idence of disease.
Case Report 3
A 77-year-old man with a long smoking history under-
went a direct microlaryngoscopy for dysphonia and dys-
pnoe over 3 months. The indirect laryngoscopy detected
the anterior subglottic tumor. The patient underwent
neck computerized tomography (CT) with contrast me-
dium which showed the presence of a mass in the right
subglottic area, obstructing the subglottic airway. CT
scan revealed lymphadenopathy in the left supraclavi-
cular fossa, and liver and lung metastases. The histolo-
gical diagnosis was small cell neuroendocrine carcinoma-
poorly differentiated (Figure 1). No immunohistochemi-
cal stains were performed on this initial biopsy. Urinary
levels of chromogranin A (CgA) and 5-hydroxyindole ace-
tic acid (5-HIAA) were increased (CgA: 23.38 mg/24h;
normal value 2–15 mg/24h; 5-HIAA: 309.8 ng/mL; nor-
mal value 0–100 ng/mL). A tracheostomy was placed.
The patient started treatment with long-acting release
octreotide but he died 4 months after diagnosis. No
post-mortem tumor workup was performed.
Case Report 4
This 47-year-old woman, who was a smoker, pre-
sented with a left neck mass of 1 month duration with oc-
casional dysphagia. On physical examination, she had 3
cm palpable left sided cervical lymphadenopathy (Figure
2). Laryngoscopy revealed a mass of the laryngeal aspect
of the epiglottis and left false vocal cord. A laryngoscopic
biopsy was performed and the neoplasm was diagnosed
as a squamous cell carcinoma. The patient underwent a
horizontal supraglottic laryngectomy and radical neck
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Fig. 1. Small cell neuroendocrine carcinoma of the larynx, show-
ing the typical oat cells, nuclear molding and a high
mitotic index (H&E, ×200).
Fig. 2. Axial contrast-enhanced computed tomographic scan with
laryngeal mass and left sided cervical lymphadenopathy.
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dissection on the left side. Based on the surgical sample a
diagnosis of small cell neuroendocrine carcinoma- grade
III was made, and confirmed after revision of the sample.
Immunohistochemistry for cytokeratins (CK) 5/6 was
positive and for neuron-specific enolase (NSE) was nega-
tive. Metastatic carcinoma was present in one of 14
lymph nodes (largest 2.8 cm). One month later the pa-
tient developed cervical lymphadenopathy on the right
side and neck dissection was performed. She was treated
with postoperative chemotherapy and radiation, com-
pleting the full course. However, she died 10 months af-
ter diagnosis.
Discussion
Neuroendocrine tumor of larynx is an extremely rare
disease classified as typical carcinoids, atypical carci-
noids, small-cell neuroendocrine carcinomas, and para-
gangliomas.
Extrapulmonary small cell carcinoma is relatively
rare disease and account for 2.5 to 5% of all small-cell
neuroendocrine carcinomas7. The larynx is one of the
most common extrapulmonary sites but this an unusual
neoplasms account for only 0.5% of all laryngeal carcino-
mas8. Small cell carcinoma of larynx was first described
by Olofsson and van Nostrand in 19729. In 2008, Ferlito
and Rinaldo reported that there were approximately 200
cases of primary and 5 of secondary small-cell neuroen-
docrine carcinomas of the larynx published in the litera-
ture at that time10.
Small-cell neuroendocrine carcinomas is also reffered
to as small cell carcinoma, oat cell carcinoma, anaplastic
cell carcinoma, anaplastic small cell carcinoma, small cell
undifferentiated carcinoma, poorly differentiated neuro-
endocrine carcinoma, neuroendocrine carcinoma, etc.
The pathological diagnosis is based on histological,
ultrastructural and immunohistochemical criteria. His-
tologically, small-cell neuroendocrine carcinomas are
classified as oat-cell, intermediate-cell, or combined-cell
types. The oat cell carcinoma is composed of small cells
with hyperchromatic nuclei and sparse cytoplasm. Cell
necrosis and mitotic activity are frequent. In the inter-
mediate cell type the cells are slightly larger with a more
abundant cytoplasm. A mixture of small cell neuroendo-
crine carcinoma with another tumor, usually squamous
cell carcinoma or adenocarcinoma is the combined type.
Based on Aggarwal et al. review, a total of 17 cases of
combined small cell carcinoma have been reported in the
literature to date11.
Immunohistochemistry is a valid adjuvant in the light
evaluation of the morphological criteria of these neo-
plasms. Small cell neuroendocrine carcinoma may be
immunoreactive with cytokeratins, EMA, CEA, and with
general neuroendocrine markers, including chromogra-
nin, neuron-specific enolase, CD56, CD57, synapthophy-
sin, neuropeptides, including calcitonin, somatostatin,
adrenocorticotropic hormone, bombesin, and serotonin.
Also, small cell neuroendocrine carcinoma may be posi-
tive for thyroid transcription factor-1 (TTF-1).
Small-cell neuroendocrine carcinomas usually arise
submucosally. Laryngeal small cell carcinoma can occur
in any region of the larynx but the most frequent site of
disease is the supraglottic region, in particular aryepi-
glottic fold, arytenoid, epiglottis. The most common
symptoms are hoarseness, dysphagia, pharyngodynia,
hemoptysis and dyspnea and differ according to the site
and the extent of disease. Subglottic small cell carcinoma
is extremely rare presented with dyspnea, hoarseness,
and dysphagia. In our series one of four cases presented
with subglottic tumor and other three patients with
supraglottic localisation.
Small-cell neuroendocrine carcinomas are very ag-
gressive neoplasms. About half of all patients present
with cervical lymph node metastases12. More than 90% of
patients with this tumor develop metastatic disease8.
They are characterized by diffuse early metastasis. The
most frequent sites of metastatic spread are the cervical
lymph nodes, bone, skin, liver and lung. Small cell neuro-
endocrine carcinoma of the larynx should be regarded as
a systemic disease13.
Neuroendocrine tumor of the larynx are rarely associ-
ated with clinically evident hormonal activity probably
due to the reduced or absent secretion or release of hor-
monal substances. Different paraneoplastic syndromes,
including Schwartz-Bartter syndrome due to inappropri-
ate secretion of antidiuretic hormone14–16, myasthenic
syndrome of Eaton-Lambert17 and ectopic adrenocortico-
tropic hormone syndrome18 have been reported in cases
of small cell neuroendocrine carcinoma of the larynx.
There is no specific treatment for neuroendocrine tu-
mors of the larynx. Our patients were presented to the
board for head and neck malignancies but also to the
board for endocrine tumors. The therapeutic approach
vary according to disease stage and these tumors are
mostly treated as squamous cell carcinomas. Baugh et al.
evaluated the various therapeutic modalities that have
been used to treat this cancer19. They found that the
combination of primary radiation therapy and adjuvant
chemotherapy resulted in significantly longer survival
than with any other treatment regimen. Important indi-
cator of poor prognosis is resistance to chemotherapy.
Surgical management of small cell neuroendocrine carci-
noma of the larynx is not so effective20. Most authors
generally agreed that surgery alone or in combination
with radiotherapy does not cure local tumor. Therefore,
radical surgical procedure is not recommended as the ini-
tial treatment of choice. Surgery for this tumor should be
reserved for cases of local relapse with no evidence of
metastasis10,21.
The prognosis of small cell neuroendocrine carcinoma
of the larynx is very poor and is similar to those for small
cell lung cancer22. Gnepp et al. reported a mean survival
time of 9.8 months (range, 1–26 months) of patients with
small cell carcinoma of the larynx23. The 2- and 5-year
survival rates are 16% and 5%, respectively12. Soga et al.
found a 5-year survival rate of 7.7%24. These survival
rates did not correlate with the size of tumor12.
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Conclusions
Laryngeal cancer is the most common head-and-neck
cancer. Neuroendocrine tumors are the most common
nonsquamous types of neoplasms arising in larynx. Ne-
uroendocrine tumor of larynx is an extremely rare dis-
ease classified as typical carcinoids, atypical carcinoids,
small-cell neuroendocrine carcinomas, and paraganglio-
mas. Small-cell neuroendocrine carcinomas are classified
as oat-cell, intermediate-cell, or combined-cell types.
Small-cell neuroendocrine carcinomas usually arise sub-
mucosally in supragllotic region. Small-cell neuroendo-
crine carcinomas are very aggressive neoplasms charac-
terized by diffuse early metastasis. There is no specific
treatment for neuroendocrine tumors of the larynx. Pa-
tients could benefit from surgery, but radiotherapy and
chemotherapy remain the treatment of choice. Small-cell
neuroendocrine carcinoma is the most lethal tumor of
the larynx with a five-year survival of 5%. Examination
of a large series is required to provide clear diagnostic
categories and to define the best treatment modalities.
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SITNOSTANI^NI NEUROENDOKRINI TUMORI GRKLJANA – MALA SERIJA SLU^AJEVA
S A @ E T A K
Neuroendokrini tumori su naj~e{}i neskvamocelularni tumori grkljana. Dijele se na: tipi~ne karcinoide, atipi~ne
karcinoide, sitnostani~ne neuroendokrine tumore i paragangliome.Cilj ovog rada je da prezentiramo ~etiri pacijenta,
jednu `enu i tri mu{karca, sa sitnostani~nim neuroendokrinim tumorom grkljana. Pacijenti su bili uzrasta od 47–77
godina i svi su imali razvijene metastaze pri prvom pregledu. U radu je diskutirano klini~ko ispoljavanje, dijagnosti~ki i
terapijski pristup pacijentima sa ovim agresivnim tipom tumora. Mada kirurgija ima odre|eno mjesto u lije~enju, radio-
terapija i kemoterapija pretstavljaju terapiju izbora. Analiza ve}eg broja slu~ajeva je potrebna kako bi se utvrdili naj-
korisniji dijagnosti~ki testovi i najefikasniji na~in lije~enja.
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